ProQR Therapeutics (PRQR) EBT Margin (2021 - 2026)
ProQR Therapeutics (PRQR) posted EBT Margin of 658.29% for Q1 2026, down 207.9% sequentially from 213.8% in Q4 2025, and down 42704.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
ProQR Therapeutics (PRQR) EBT Margin (2021 - 2026) Analysis & Trends
ProQR Therapeutics has reported EBT Margin for 14 years, with the latest figure at 658.29% in Q1 2026.
- Quarterly EBT Margin fell 42704.0% year-over-year to 658.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 347.57% (down 18576.0% YoY) and the FY2025 annual result came in at 272.03%, down 12413.0% from the prior year.
- EBT Margin retreated to 658.29% in Q1 2026 per PRQR's latest filing, from 213.8% in the prior quarter.
- Over five years, EBT Margin peaked at 45.87% in Q2 2024 and troughed at 2854.42% in Q3 2022.
- A 5-year average of 733.51% and a median of 381.89% in 2025 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 577537 bps in 2022, down 114448 bps in 2022.
- Over 5 years, EBT Margin stood at 1847.22% in 2022, then jumped by 89 bps to 207.06% in 2023, then retreated by 4 bps to 216.04% in 2024, then advanced by 1 bps to 213.8% in 2025, then tumbled by 208 bps to 658.29% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 658.29%, 213.8%, and 381.89% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | ProQR Therapeutics | 218.57 Mn | 82.18 Mn | - | -99.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -99.36% |
| Mar 31, 2026 | -658.29% |
| Dec 31, 2025 | -186.51% |
| Sep 30, 2025 | -381.89% |
| Jun 30, 2025 | -318.60% |
| Mar 31, 2025 | -223.04% |
| Dec 31, 2024 | -216.04% |
| Sep 30, 2024 | -210.98% |
| Jun 30, 2024 | -45.87% |
| Mar 31, 2024 | -172.02% |
| Dec 31, 2023 | -166.81% |
| Sep 30, 2023 | -398.61% |
| Jun 30, 2023 | -665.48% |
| Mar 31, 2023 | -1,351.91% |
| Dec 31, 2022 | -1,847.22% |
| Sep 30, 2022 | -2,854.42% |
| Jun 30, 2022 | -1,447.63% |
| Mar 31, 2022 | -1,248.67% |
| Dec 31, 2021 | -7,622.59% |
| Sep 30, 2021 | -1,724.08% |